3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

D.Freeman; T.Juan; N.J.Meropol; J.R.Hecht; J.Berlin; E.van Cutsem; M.Reiner; R.Radinsky; R.G.Amado; M.Peeters

首页> 外文期刊>European Journal of Cancer Supplements >3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

【24h】

3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

机译：3014（总统会议，9月25日星期二，12月30日至14.30）ORAL接受帕尼单抗单药治疗的转移性结直肠癌（mCRC）患者的体KRAS基因突变与临床结局的关联

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
D.Freeman; T.Juan; N.J.Meropol; J.R.Hecht; J.Berlin; E.van Cutsem; M.Reiner; R.Radinsky; R.G.Amado; M.Peeters;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. 3019 POSTER Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy [J] . J.Berlin, J.R.Hecht, M.Reiner, European Journal of Cancer Supplements . 2007,第4期

机译：3019 POSTER帕尼单抗单药治疗的转移性结直肠癌（mCRC）患者的表皮生长因子受体（EGFr）基因拷贝数（GCN）与临床结局的关联
2. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy [J] . R.G. Amado, . M. Wolf, D. Freeman, European Journal of Cancer Supplements . 2007,第6期

机译：帕尼单抗单药治疗转移性结直肠癌患者KRAS突变分析
3. 7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy [J] . R.G.Amado, M.Wolf, D.Freeman, European Journal of Cancer Supplements . 2007,第6期

机译：帕尼单抗单药治疗转移性结直肠癌患者KRAS突变的7LB分析
4. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in metastatic colorectal cancer (mCRC) patients treated with salvage cetuximab/panitumumab monotherapy [O] . Zenia Saridaki, Joanne B. Weidhaas, Heinz-Josef Lenz, -1

机译：KRAS的let-7 microRNA结合位点多态性预测接受挽救性西妥昔单抗/帕尼单抗单药治疗的转移性结直肠癌（mCRC）患者的转归改善
5. PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING PANITUMUMAB IN GREECE [O] . Papagianopoulou V, Christodoulopoulou A, Bracco A, 2008

机译：PCN17估计在接受胰腺癌的转移性大肠直肠癌（MCRC）患者中引入KRAS检测可节省成本

3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

著录项

相似文献

相关主题

期刊订阅